Intrarosa™ contains the active substance prasterone.
What Intrarosa™ is used for
Intrarosa™ is used to treat postmenopausal women having moderate to severe symptoms of vulvar and
vaginal atrophy. It is used to relieve menopausal symptoms in the vagina such as dryness or irritation. It is
caused by a drop in the levels of oestrogen in your body. This happens naturally after the menopause.
How Intrarosa™ works
Prasterone corrects the symptoms and signs of vulvar and vaginal atrophy by replacing the oestrogens
which are normally produced before menopause by the ovaries of women. It is inserted into your vagina,
so the hormone is released where it is needed. This may relieve discomfort in the vagina.
 

The use of HRT carries risks which need to be considered when deciding whether to start taking it, or
whether to carry on taking it.
The experience in treating women with a premature menopause (due to ovarian failure or surgery) is limited.
If you have a premature menopause the risks of using HRT may be different. Please talk to your doctor.
Before you start (or restart) HRT, your doctor will ask about your own and your family’s medical history.
Your doctor may decide to perform a physical examination. This may include an examination of your
breasts and/or an internal examination, if necessary.
Once you have started on Intrarosa™ you should see your doctor for regular check-ups (at least every 6
months). At these check-ups, discuss with your doctor the benefits and risks of continuing with
Intrarosa™.
Go for regular breast screening, as recommended by your doctor.
Do not take Intrarosa™
if any of the following applies to you. If you are not sure about any of the points below, talk to your
doctor before taking Intrarosa™,
• If you have or have ever had breast cancer, or if you are suspected of having it;
• If you have cancer which is sensitive to oestrogens, such as cancer of the womb lining (endometrium),
or if you are suspected of having it;
• If you have any unexplained vaginal bleeding;
• If you have excessive thickening of the womb lining (endometrial hyperplasia ) that is not being
treated;
• If you have or have ever had a blood clot in a vein (thrombosis), such as in the legs (deep venous
thrombosis) or the lungs (pulmonary embolism);
• If you have a blood clotting disorder (such as protein C, protein S, or antithrombin deficiency);
• If you have or recently have had a disease caused by blood clots in the arteries, such as a heart attack,
stroke or angina;
• If you have or have ever had a liver disease and your liver function tests have not returned to normal;
• If you have a rare blood problem called “porphyria” which is passed down in families (inherited);
• If you are allergic (hypersensitive) to prasterone or any of the other ingredients of Intrarosa™ (listed in
section 6 Further information).
If any of the above conditions appears for the first time while taking Intrarosa™, stop taking it at once
and consult your doctor immediately.

Warnings and precautions
When to take special care with Intrarosa™
Tell your doctor if you have ever had any of the following problems, before you start the treatment, as
these may return or become worse during treatment with Intrarosa™. If so, you should see your doctor
more often for check-ups:
• fibroids inside your womb;
• growth of womb lining outside your womb (endometriosis) or a history of excessive growth of the
womb lining (endometrial hyperplasia);
• increased risk of developing blood clots (see “Blood clots in a vein (thrombosis)”);
• increased risk of getting a oestrogen-sensitive cancer (such as having a mother, sister or grandmother who
has had breast cancer);
• high blood pressure;
• a liver disorder, such as a benign liver tumour;
•diabetes;
• gallstones;
• migraine or severe headaches;
• a disease of the immune system that affects many organs of the body (systemic lupus erythematosus,
SLE);
• epilepsy;
• asthma;
• a disease affecting the eardrum and hearing (otosclerosis);
• a very high level of fat in your blood (triglycerides);
• fluid retention due to cardiac or kidney problems.
Stop taking Intrarosa™ and see a doctor immediately
If you notice any of the following when taking HRT:
• any of the conditions mentioned in the ‘DO NOT take Intrarosa™’ section;
• yellowing of your skin or the whites of your eyes (jaundice). These may be signs of a liver disease;
• if you become pregnant;
• a large rise in your blood pressure (symptoms may be headache, tiredness, dizziness);
• migraine-like headaches which happen for the first time;
• if you notice signs of a blood clot, such as:
- painful swelling and redness of the legs;
- sudden chest pain;
- difficulty in breathing.
For more information, see ‘Blood clots in a vein (thrombosis)’
Note: Intrarosa™ is not a contraceptive. If it is less than 12 months since your last menstrual period or you
are under 50 years old, you may still need to use additional contraception to prevent pregnancy. Speak to
your doctor for advice.
HRT and cancer
Intrarosa™ has not been studied in women with current or history of cancers.
Excessive thickening of the lining of the womb (endometrial hyperplasia) and cancer of the lining of
the womb (endometrial cancer)
Taking oestrogen-only HRT tablets for a long time can increase the risk of developing cancer of the womb
lining (the endometrium). Intrarosa™ does not stimulate the endometrium as shown by atrophy of the lining
of the womb in all women treated with Intrarosa™ for one year during the clinical trials.
It is uncertain whether a risk exists with Intrarosa™ used for long term (more than one year) treatments.
However, Intrarosa™ has been shown to have very low absorption into the blood, therefore the addition
of a progestagen is not necessary.
If you get bleeding or spotting, it’s usually nothing to worry about, but you should make an appointment to
see your doctor. It could be a sign that your endometrium has become thicker.
The following risks apply to HRT medicines which circulate in the blood. However Intrarosa™ is for
local treatment in the vagina and the absorption into the blood is very low. It is less likely that the
conditions mentioned below will get worse or come back during treatment with Intrarosa™, but you
should see your doctor if you are concerned.
Breast cancer
Evidence suggests that taking combined oestrogen-progestogen and possibly also oestrogen-only HRT
increases the risk of breast cancer. The extra risk depends on how long you take HRT. The additional risk
becomes clear within a few years. However, it returns to normal within a few years (at most 5) after
stopping treatment.
• Regularly check your breasts. See your doctor if you notice any changes such as:
• dimpling of the skin;
• changes in the nipple;
• any lumps you can see or feel.
Additionally, you are advised to join mammography screening programs when offered to you.
Ovarian cancer
Ovarian cancer is rare - much rarer than breast cancer. The use of oestrogen-only HRT has been associated
with a slightly increased risk of ovarian cancer.
The risk of ovarian cancer varies with age. For example, in women aged 50 to 54 who are not taking HRT,
about 2 women in 2000 will be diagnosed with ovarian cancer over a 5-year period. For women who have
been taking HRT for 5 years, there will be about 3 cases per 2000 users (i.e. about 1 extra case).
Cases of ovarian and breast cancer have rarely been reported in women treated with 6.5 mg of prasterone
for 52 weeks.
Effect of HRT on heart and circulation
Intrarosa™ has not been studied in women with history of thromboembolic diseases, uncontrolled
hypertension or heart disease.
Blood clots in a vein (thrombosis)
The risk of blood clots in the veins is about 1.3 to 3-times higher in HRT users than in non-users,
especially during the first year of taking it.
Blood clots can be serious, and if one travels to the lungs, it can cause chest pain, breathlessness, fainting
or even death.
You are more likely to get a blood clot in your veins as you get older and if any of the following applies
to you. Inform your doctor if any of these situations applies to you:
• you are unable to walk for a long time because of major surgery, injury or illness (see also section
3, If you need to have surgery);
• you are seriously overweight (BMI >30 kg/m2);
• you have any blood clotting problem that needs long-term treatment with a medicine used to
prevent blood clots;
• if any of your close relatives has ever had a blood clot in the leg, lung or another organ;
• you have systemic lupus erythematosus (SLE);
• you have cancer.
For signs of a blood clot, see “Stop taking Intrarosa™ and see a doctor immediately”.
In clinical trials, no deep vein thrombosis has been observed with intravaginal prasterone while one case of
pulmonary embolism which corresponds to an incidence lower with Intrarosa™ than in the placebo group.
Compare
Looking at women in their 50s who are not taking HRT, on average, over a 5-year period, 4 to 7 in 1000
would be expected to get a blood clot in a vein.
Heart disease (heart attack) / Hypertension
For women taking oestrogen-only therapy there is no increased risk of developing a heart disease.
Stroke
The risk of getting stroke is about 1.5 times higher in HRT users than in non-users. The number of extra
cases of stroke due to use of HRT will increase with age.
No case of stroke has been observed with Intrarosa™ during clinical trials.
Compare
Looking at women in their 50s who are not taking HRT, on average, 8 in 1000 would be expected to have
a stroke over a 5-year period. For women in their 50s who are taking HRT, there will be 11 cases in 1000
users, over 5 years (i.e. an extra 3 cases).
Other conditions
• HRT will not prevent memory loss. There is some evidence of a higher risk of memory loss in women
who start using HRT after the age of 65. Speak to your doctor for advice;
• You may have vaginal discharge due to melting of the ‘hard fat base’ which adds to increased vaginal
secretions due to treatment. If vaginal discharge occurs, it is not required to stop Intrarosa™.
• Intrarosa™ may weaken condoms, diaphragms and cervical caps made of latex.
• If you have a vaginal infection you will need a course of antibiotics before taking Intrarosa™.
Children and adolescents
Intrarosa™ is only used in adult women.
Other medicines and Intrarosa™
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
No data on efficacy and safety are available in women currently treated with hormonal therapy such as:
androgens, hormone replacement therapy (oestrogen alone or combined with progestogens).
The use of Intraorsa in combination with hormone replacement therapy (oestrogen-only or oestrogenprogestagen
combination or androgen treatment) or vaginal oestrogens is not recommended.
Pregnancy, breast feeding and fertility
Pregnancy and breast feeding
Intrarosa™ is for use in postmenopausal women only. If you become pregnant, stop taking Intrarosa™
and contact your doctor.
Fertility
Intrarosa™ is not meant for women with child-bearing potential. It is not known if this medicine affects
fertility.
Driving and using machines
Intrarosa™ does not affect your ability to drive and use machines.

Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or
pharmacist if you are not sure.
Your doctor will aim to prescribe the lowest dose to treat your symptom for as short as necessary. Speak
to your doctor if you think this dose is too strong or not strong enough.
How much to use
Use one pessary once a day, at bedtime.
How to use
Insert the pessary into the vagina with your finger or with an applicator provided in the pack.
Before you start
• Empty your bladder and wash your hands before handling the pessary and applicator.
• Tear off one wrapped pessary from the 7-pessary strip.
A. Using the applicator
STEP 1
• 1A. Remove 1 applicator from
the package.
• 1B. Pull back on the plunger
until it stops to activate the
applicator. The applicator must be
activated before use. Place the
applicator on a clean surface.
STEP 5
• Select the position for insertion of
the pessary that is most comfortable
for you.
5a. Lying position
STEP 2
• Slowly pull the plastic tabs on the
pessary away from eac h other while
keeping the pessary still between
your fingers.
• Carefully remove the pessary from
the plastic wrap.
• If a pessary falls on an unsanitary
surface, replace it with a new one.
5b. Standing position
STEP 3
• Place the flat end of the pessary
into the open end of the activated
applicator as shown. You are now
ready to insert the pessary into your
vagina.
STEP 6
• Gently slide the pessary end of the
applicator into your vagina as far as
it will comfortably go.
Do not use force.
STEP 4
• Hold the applicator between your
thumb and middle finger.
• Leave your index (pointer) finger
free to press the applicator plunger
after the applicator is inserted into
your vagina.
STEP 7
• Press the applicator plunger with
your index (pointer) finger to
release the pessary.
• Remove the applicator. Wash it or
throw it away after using for one
week (see details in section 3 -
“How to use Intrarosa™”)
B. Using the finger
Follow the above instructions of Step 2, and then insert the pessary into the vagina with your finger as far as it
can comfortably go. Do not use force.
How long to use
After initial use, see your doctor at least every 6 months to check if you need to keep using Intrarosa™.
If you use more Intrarosa™ than you should
Vaginal douching is recommended.
If you forget to use Intrarosa™
If you forget to use a pessary, insert one as soon as you remember. However, if the next dose is due in
less than 8 hours, skip the missed pessary.
Do not use two pessaries to make up for a forgotten dose.
If you need to have surgery
If you are going to have surgery, tell the surgeon that you are taking Intrarosa™. You may need to stop
taking Intrarosa™ about 4 to 6 weeks before the operation to reduce the risk of a blood clot (see section 2,
Blood clots in a vein). Ask your doctor when you can start taking Intrarosa™ again.

Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following diseases are reported more often in women using HRT medicines which circulate in the
blood compared to women not using HRT. These risks apply less to vaginally administered oestrogen
treatments:
• breast cancer;
• ovarian cancer;
• blood clots in the veins of the legs or lungs (venous thromboembolism);
• stroke;
• probable memory loss if HRT is started over the age of 65.
For more information about these side effects, see section 2.
The side effect the most frequently reported in the clinical studies was vaginal discharge. This is likely
due to melting of the hard fat added to an expected increase in vaginal secretions due to treatment.
Vaginal discharge does not require to stop Intrarosa™.
The following adverse effects were also reported:
− with a common frequency (may affect up to 1 in 10 people): abnormal Pap smear (mostly ASCUS or
LGSIL), weight fluctuations (either increase or decrease);
− with a uncommon frequency (may affect up to 1 in 100 people): benign cervical or uterine polyps,
benign breast mass.
The following side effects have been reported with HRT containing estrogens but not with Intrarosa™
during clinical trials:
• gall bladder disease
• various skin disorders:
- discoloration of the skin especially of the face or neck known as “pregnancy patches”
(chloasma);
- painful reddish skin nodules (erythema nodosum);
- rash with target-shaped reddening or sores (erythema multiforme).

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blisters after EXP. The
expiry date refers to the last day of that month.
Do not store above 30 °C.
Do not freeze.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw
away medicines you no longer use. These measures will help protect the environment.